These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8305239)

  • 1. Immunoconjugate stability in vivo measured by label release from 125I or 99mTc-antibody coated cells kept in intraperitoneal diffusion chambers in mice.
    Fjeld J; Brorson B; Martinussen GK; Benestad H; Nustad K
    Acta Oncol; 1993; 32(7-8):873-6. PubMed ID: 8305239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo instability of reduction-mediated 99mTc-labeled monoclonal antibody.
    Sakahara H; Saga T; Endo K; Hattori N; Hosono M; Kobayashi H; Shirato M; Yamamuro T; Toyama S; Arano Y
    Nucl Med Biol; 1993 Jul; 20(5):617-23. PubMed ID: 8358347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor.
    Kurth M; Pèlegrin A; Rose K; Offord RE; Pochon S; Mach JP; Buchegger F
    J Med Chem; 1993 Apr; 36(9):1255-61. PubMed ID: 8487262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technetium-99m-labeled antibodies. Stability compared to 125I labeled antibodies.
    Gooden CS; Snook DE; Epenetos AA
    Cell Biophys; 1993; 22(1-3):49-59. PubMed ID: 7889542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
    Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
    J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
    Shin IS; Jang BS; Danthi SN; Xie J; Yu S; Le N; Maeng JS; Hwang IS; Li KC; Carrasquillo JA; Paik CH
    Bioconjug Chem; 2007; 18(3):821-8. PubMed ID: 17375899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of 111In- and 125I-labeled monoclonal antibody 17-1A in mice bearing xenografts of human pancreatic carcinoma HuP-T4.
    Maeda M; Shoji M; Kawagoshi T; Futatsuya R; Honda T; Brady LW
    Cancer; 1994 Feb; 73(3 Suppl):800-7. PubMed ID: 8306263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes.
    Patel HM; Boodle KM; Vaughan-Jones R
    Biochim Biophys Acta; 1984 Sep; 801(1):76-86. PubMed ID: 6087919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy.
    Kim EJ; Kim BS; Choi DB; Chi SG; Choi TH
    Oncol Rep; 2016 Jun; 35(6):3159-68. PubMed ID: 27035553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies.
    Ram S; Buchsbaum DJ
    Cancer; 1994 Feb; 73(3 Suppl):769-73. PubMed ID: 8306258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.
    Fjeld JG; Benestad HB; Stigbrand T; Nustad K
    Br J Cancer; 1992 Jul; 66(1):74-8. PubMed ID: 1637680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct technetium-99m labeling of three anticancer monoclonal antibodies: stability, pharmacokinetics and imaging.
    Gooden CS; Snook DE; Maraveyas A; Rowlinson-Busza G; Peters AM; Epenetos AA
    J Nucl Med; 1995 May; 36(5):842-9. PubMed ID: 7738662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
    Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
    Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evaluation of radiolabelled antibodies with antigen-coated polymer particles in diffusion chambers.
    Fjeld JG; Benestad HB; Stigbrand T; Nustad K
    J Immunol Methods; 1988 Apr; 109(1):1-7. PubMed ID: 3356905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotargeting of human tumour cells in immunocompetent animals.
    Fjeld JG; Bruland OS; Benestad HB; Schjerven L; Stigbrand T; Nustad K
    Br J Cancer; 1990 Oct; 62(4):573-8. PubMed ID: 2223574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo study of a technetium labelled anti-EGFr MoAB.
    Scopinaro F; De Vincentis G; Banci M; Schillaci O; Di Loreto M; Danieli R; Ierardi M; De Paola AM; Gianni W; Massa R
    Anticancer Res; 1997; 17(3B):1761-5. PubMed ID: 9179231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability.
    Arano Y; Yokoyama A; Furukawa T; Horiuchi K; Yahata T; Saji H; Sakahara H; Nakashima T; Koizumi M; Endo K
    J Nucl Med; 1987 Jun; 28(6):1027-33. PubMed ID: 3585492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
    Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.